This content is in French.
A breakthrough in pancreatic cancer treatment: evaluation of a new dual therapy
29 novembre 2024
Pancreatic ductal adenocarcinoma (PDA) is one of the leading causes of
cancer-related mortality. This malignancy is characterized by its resistance to
conventional treatments and immune checkpoint inhibitors (ICIs). Due to its
late detection, poor long-term survival rate, and rising incidence, identifying
new therapeutic approaches remains a critical priority.
In this context, this study investigates the combination of entinostat—an inhibitor of histone deacetylases (HDACi)—and nivolumab—a PD-1 inhibitor—as a dual therapy designed to remodel the tumor microenvironment and stimulate immune responses in patients with advanced PDA.
In this context, this study investigates the combination of entinostat—an inhibitor of histone deacetylases (HDACi)—and nivolumab—a PD-1 inhibitor—as a dual therapy designed to remodel the tumor microenvironment and stimulate immune responses in patients with advanced PDA.
An effective dual therapy for advanced PDA?
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Baretti, M., et al. (2024). Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial. Nature communications, 15(1), 9801.
View the source
